These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 36323431)

  • 1. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
    Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
    Sum E; Rapp M; Dürr H; Mazumdar A; Romero PJ; Trumpfheller C; Umaña P
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
    Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
    Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
    Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
    Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
    Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
    Enell Smith K; Deronic A; Hägerbrand K; Norlén P; Ellmark P
    Expert Opin Biol Ther; 2021 Dec; 21(12):1635-1646. PubMed ID: 34043482
    [No Abstract]   [Full Text] [Related]  

  • 7. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.
    Salomon R; Rotem H; Katzenelenbogen Y; Weiner A; Cohen Saban N; Feferman T; Amit I; Dahan R
    Nat Cancer; 2022 Mar; 3(3):287-302. PubMed ID: 35190724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation CD40 agonists for cancer immunotherapy.
    Andersson H; Nyesiga B; Hermodsson T; Enell Smith K; Hägerbrand K; Lindstedt M; Ellmark P
    Expert Opin Biol Ther; 2024 May; 24(5):351-363. PubMed ID: 38764393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
    Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
    Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
    Wooldridge JE; Dahle CE; Weiner GJ
    Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
    de Weerdt I; Lameris R; Scheffer GL; Vree J; de Boer R; Stam AG; van de Ven R; Levin MD; Pals ST; Roovers RC; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
    Cancer Immunol Res; 2021 Jan; 9(1):50-61. PubMed ID: 33177109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
    Houtenbos I; Santegoets S; Westers TM; Waisfisz Q; Kipriyanov S; Denkers F; Scheper RJ; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2008 Jun; 142(2):273-83. PubMed ID: 18492117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
    Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
    Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
    Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.